TR201909923T4 - Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon. - Google Patents

Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon. Download PDF

Info

Publication number
TR201909923T4
TR201909923T4 TR2019/09923T TR201909923T TR201909923T4 TR 201909923 T4 TR201909923 T4 TR 201909923T4 TR 2019/09923 T TR2019/09923 T TR 2019/09923T TR 201909923 T TR201909923 T TR 201909923T TR 201909923 T4 TR201909923 T4 TR 201909923T4
Authority
TR
Turkey
Prior art keywords
prevention
treatment
kidney disease
composition containing
pyrazole derivative
Prior art date
Application number
TR2019/09923T
Other languages
English (en)
Inventor
Soo Bae Yun
Joo Ha Hun
In Lee Kee
Hee Song Kyung
Original Assignee
Univ Ewha Ind Collaboration
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ewha Ind Collaboration filed Critical Univ Ewha Ind Collaboration
Publication of TR201909923T4 publication Critical patent/TR201909923T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Mevcut buluş, istemlerde tanımlandığı gibi böbrek hastalığının önlenmesi ya da tedavisi için bir kompozisyon ile ilgilidir.
TR2019/09923T 2012-08-27 2013-08-02 Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon. TR201909923T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
TR201909923T4 true TR201909923T4 (tr) 2019-07-22

Family

ID=50183832

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09923T TR201909923T4 (tr) 2012-08-27 2013-08-02 Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon.

Country Status (9)

Country Link
US (1) US10047067B2 (tr)
EP (1) EP2889032B1 (tr)
JP (1) JP5974180B2 (tr)
KR (1) KR101633957B1 (tr)
CN (1) CN104755077B (tr)
ES (1) ES2734264T3 (tr)
PL (1) PL2889032T3 (tr)
TR (1) TR201909923T4 (tr)
WO (1) WO2014035070A1 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101826208B1 (ko) 2016-02-05 2018-02-06 경북대학교 산학협력단 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
WO2021101344A1 (ko) 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
EP4134079A4 (en) * 2020-04-08 2024-04-24 Aptabio Therapeutics Inc AGENTS FOR THE TREATMENT OF CONTRAST MEDIA-INDUCED ACUTE KIDNEY INJURY
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
CN115427039A (zh) * 2020-04-13 2022-12-02 阿普塔生物治疗公司 包含吡唑衍生物的肺纤维化药物
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
KR102589130B1 (ko) 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
AU2697092A (en) 1991-10-08 1993-05-03 Nippon Soda Co., Ltd. Pyrazole derivative and agrohorticultural bactericide containing same
JP2003098120A (ja) 2001-09-26 2003-04-03 Tokyo Weld Co Ltd 外観検査装置
JP4189850B2 (ja) * 2002-05-20 2008-12-03 味の素株式会社 線維化病変組織修復剤
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
WO2006129587A1 (ja) * 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
US7994094B2 (en) * 2006-09-01 2011-08-09 Otsuka Agritechno Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent
KR100942382B1 (ko) * 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
WO2011028044A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
US8604210B2 (en) * 2009-09-02 2013-12-10 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same

Also Published As

Publication number Publication date
KR20140027833A (ko) 2014-03-07
CN104755077B (zh) 2018-05-15
EP2889032A4 (en) 2016-03-09
EP2889032B1 (en) 2019-05-08
CN104755077A (zh) 2015-07-01
JP2015531774A (ja) 2015-11-05
WO2014035070A1 (ko) 2014-03-06
US20150218125A1 (en) 2015-08-06
KR101633957B1 (ko) 2016-06-27
ES2734264T3 (es) 2019-12-05
JP5974180B2 (ja) 2016-08-23
US10047067B2 (en) 2018-08-14
EP2889032A1 (en) 2015-07-01
PL2889032T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
TR201909923T4 (tr) Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon.
CY1124431T1 (el) Συριγγα
MY173843A (en) Amidine substituted ?-lactam compounds, their preparation and use as antibacterial agents
EA201590321A1 (ru) Дейтерированный барицитиниб
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
TR201902788T4 (tr) Nörodejeneratif hastalıkların tedavisinde kullanışlı 1-arilkarbonil-4-oksi-piperidin bileşikleri.
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201590887A1 (ru) Композиция
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201590962A1 (ru) Новые соединения
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
EA201591451A1 (ru) Модуляторы flap
BR112015001697A2 (pt) formulações de clomazona
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
EA201290642A1 (ru) Соединения и способы
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
CY1119470T1 (el) Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη
MX336204B (es) Una composicion y uso de la misma en el tratamiento de ragades anales.